Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction
- 1 March 1985
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 37 (5), 567-572
- https://doi.org/10.1016/0049-3848(85)90089-1
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarctionJournal of the American College of Cardiology, 1984
- Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.Circulation, 1983
- Systemic thrombolytic therapy of acute myocardial infarction?Circulation, 1983
- Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.Circulation, 1983
- Streptokinase and anisoylated streptokinase plasminogen complexEuropean Journal of Clinical Pharmacology, 1983
- A Comparison of Acylated Streptokinase-Plasminogen Complex and Streptokinase in Healthy VolunteersThrombosis and Haemostasis, 1982
- On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921)Thrombosis Research, 1981
- Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapyNature, 1981